Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TK1 | P04183 | 3/20 | 0.61 |
| ▸ | TYMS | P04818 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263768 | 1.00 | POLB (0.64) | POLBTK1TYMS | |
| SCHEMBL15216188 | 1.00 | POLB (0.64) | POLBTK1TYMS | |
| SCHEMBL3694340 | 0.91 | POLB (0.64) | POLBTK1 | |
| SCHEMBL9296372 | 0.90 | POLB (0.61) | POLBTK1TYMS | |
| SCHEMBL15499670 | 0.89 | TK1 (0.56) | TK1 | |
| SCHEMBL5179276 | 0.89 | ABCG2 (0.61) | POLBTK1TYMS | |
| SCHEMBL6129437 | 0.88 | POLB (0.61) | POLBTK1 | |
| SCHEMBL16057148 | 0.88 | POLB (0.61) | POLBTK1 | |
| SCHEMBL13445173 | 0.88 | POLB (0.61) | POLBTK1 | |
| SCHEMBL8999366 | 0.88 | POLB (0.61) | POLBTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111770928-A | Synthesis of oligonucleotides and nucleic acids | 埃万奈蒂克有限公司 | 2020-10-13 | — | — | CN | disclosed |
| EP-2294076-B1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED REPLICATION OF NUCLEIC ACID | TRILINK BIOTECHNOLOGIES (US) | 2017-03-08 | — | — | EP | disclosed |
| US-8133669-B2 | Chemically modified nucleoside 5′-triphosphates for thermally initiated amplification of nucleic acid | TRILINK BIOTECHNOLOGIES (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2294076-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink BioTechnologies (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009607-A1 | METHOD FOR PREPARING DNA FRAGMENT HAVING STICKY END | THE UNIVERSITY OF TOKYO (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2270142-A1 | METHOD OF PREPARING DNA FRAGMENT HAVING STICKY END | The University of Tokyo (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100003724-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink Bio Technologies | 2010-01-07 | — | — | US | disclosed |
| WO-2009151921-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TRILINK BIOTECHNOLOGIES (US) | 2009-12-17 | — | — | WO | disclosed |
| US-6900301-B2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2004101582-A2 | THERMOLABILE HYDROXYL PROTECTING GROUPS AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0638586-B1 | Nucleoside derivatives and methods for producing them | AJINOMOTO KK (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-5750669-A | NUCLEASE-STABLE ANTIVIRAL AGENTS WHICH CAN SUPPRESS SYNTHESIS OF ANTIGENS AND GENE EXPRESSION OF PROTEINS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
| US-5633366-A | Pyrimidine nucleoside derivatives and methods for producing them | AJINOMOTO CO., INC. (JP) | 1997-05-27 | — | — | US | disclosed |
| EP-0464638-B1 | Oligonucleotide analogues with terminal 3'-3' or 5'-5'-internucleotide linkages | HOECHST AG (DE) | 1997-04-02 | — | — | EP | disclosed |
| EP-0638586-A2 | Nucleoside derivatives and methods for producing them | Ajinomoto Co., Inc. (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0548189-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE. | STERLING WINTHROP INC (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5138045-A | POLYAMINE CONJUGATED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS (US) | 1992-08-11 | — | — | US | disclosed |
| WO-1992004364-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE | STERLING WINTHROP INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0464638-A2 | Oligonucleotide analogues with terminal 3'-3' or 5'-5'-internucleotide linkages | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009607-A1 | METHOD FOR PREPARING DNA FRAGMENT HAVING STICKY END | POLB, POLL, POLN | POLB 1/4885TK1 154/4885TYMS 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.